Een gerandomiseerde Fase 2-Trial of Nivolumab and Stereotactic Ablative Body Radiotherapie in Gevorderd Non-Small Cell Longkanker, Progressing After First- or Second-Line Chemotherapy (NIVORAD)

Programmed cell death protein-1 inhibitors have improved metastatic non-small cell lung cancer (NSCLC) prognosis. Stereotactic ablative body radiation therapy (SABR) may enhance immunity. This study evaluated the activity and safety of adding SABR to first-line immunotherapy post chemotherapy with nivolumab for metastatic NSCLC.